neoepitope-derived multipeptide vaccine

A **neoepitope-derived multipeptide vaccine** is a personalized cancer immunotherapy composed of multiple short peptides (neoepitopes) derived from tumor-specific mutations. These neoepitopes are selected through sequencing and immunoinformatic analysis of a patient’s tumor, and formulated together, often with adjuvants, to stimulate a targeted immune response primarily by activating T cells (both CD4+ and CD8+) against the cancer. The vaccine aims to provoke both humoral and cellular immunity—enhancing IFNγ and granzyme B secretion, increasing CD4+ and CD8+ T cell populations, and promoting anti-tumor responses while minimizing risks of off-target or autoimmunity. It is under study for several solid tumors (e.g., melanoma, pancreatic cancer, NSCLC, colorectal cancer), usually in combination with checkpoint inhibitors or chemotherapy, with clinical trials showing induction of neoepitope-specific immunity and preliminary improvements in relapse-free or progression-free survival. Multiple companies and research consortia are developing these vaccines, typically tailored individually for each patient[1][2][3][4][5].

Other names

neoepitope multipeptide vaccinemulti-neoepitope vaccinepersonalized neoepitope vaccine